Nanosystem LTD is an innovative company. The purpose of its research activities is the development of innovative drugs based on biodegradable and biocompatible nanoparticles.
Nanosystem LTD has its own research facilities that are well equipped for the preparation and physicochemical characterization of the nanoparticles. The equipment includes a zetasizer, homogenizers of various types such as high pressure, high shear, and ultrasonic homogenizers, analytical centrifuge, spectrophotometer, freeze-drier, etc.
Company′s main projects are focused on the development of the nanoparticle-based drugs for the treatment of cancers, tuberculosis and other socially important diseases. Nanosystem is also developing nanoparticles for diagnostic purposes.
The R&D strategy is based on combining the valuable properties of established pharmaceuticals with the advantages of the innovative biotechnological approach.
By focusing on the reformulation and delivery of approved pharmaceutical agents with known safety and efficacy, the company is able to capitalize on existing data by employing drug delivery systems, thereby reducing overall development risks while at the same time shortening the time, resources, and cost of developing novel products.
Nanosystem also performs the development of the nanoparticulate formulations for Russian and foreign pharmaceutical companies.
Indeed, Nanosystems′s proprietary technologies also can prolong the lifecycle of the best-selling drugs and thus can protect precious revenue from generic copies.
Intravenous formulation of the antituberculosis antibiotic rifabutin
Rifabutin is a second-line antituberculosis drug, highly active against Mycobacterium tuberculosis strains, both sensitive and resistant to rifampin. The disadvantages of oral rifabutin are its low bioavailability and pronounced gastrointestinal toxicity. An intravenous formulation of rifabutin so far is not available due to the poor drug solubility in water. Obviously, rifabutin is a good candidate for the development of the nanoparticle formulation suitable for intravenous use. Thus Nanosystem has focused the efforts on the development of such formulations of rifabutin with the purpose to improve the aforementioned disadvantages.
Extending the spectrum of drug activity: Overcoming the blood-brain barrier
Brain is one of the least accessible organs for pharmacotherapy due to the presence of the blood-brain barrier (BBB) which regulates the entrance of the solutes into the CNS (brain). Glioblastoma multiforme is one of the most severe CNS diseases and the most frequent primary brain tumour. The prognosis for the patients is very unfavourable: most of them die within two years after diagnosis.The first-line treatment for brain tumours is debulking surgery in combination with radiotherapy.
However, total tumour resection is mostly impossible. At the same time, chemotherapy plays only adjuvant role because many drugs potentially useful for the treatment of the CNS diseases demonstrate high activity in vitro but appear to be ineffective in vivo. This lack of efficacy is due to the inability of these drugs to cross the BBB and reach the brain.
Thus doxorubicin, a wide-spectrum and very potent antitumour drug so far could not be used for the chemotherapy of glioblastomas because due to the BBB it could not reach the brain in the sufficient concentrations.
In collaboration with the Goethe University (Frankfurt/Main, Germany), Nanosystem has developed the technology for brain delivery of doxorubicin with nanoparticles. The key parameter of this technology is the surface modification of the nanoparticles which enables their passage across the BBB.
Decreasing doxorubicin toxicity
The toxicological parameters of the nanoparticulate doxorubicin have been thoroughly investigated. Application of doxorubicin in the clinical practice is limited by its severe, often lethal cardiotoxicity. Nanosystem had shown that the nanoparticulate formulation enabled a considerable decrease of cardiotoxicity. This lower cardiotoxicity of the nanoparticle-bound doxorubicin is a result of the drastically decreased uptake of the nanoparticles by the myocardium.
Therefore, the nanoparticle-bound doxorubicin opens up new horizons for non-invasive chemotherapy of brain tumours.
The obvious advantages of this technology is its relative simplicity and safety for a patient.
Enhanced efficacy of nanoparticulate formulations of aminoglycoside antibiotics
The single intravenous administration of the nanoparticulate formulations of streptomycin or gentamycin cured 60-70% of the animals with acute septic infection, whereas in the groups treated with standard formulations only 20% of the animals survived. This high efficacy of the nanoparticulate aminoglycosides is due to their very fast and effective penetration into the infected cells (macrophages), whereas the uptake of free antibiotics by these cells is rather slow.